Q-learning is a method of reinforcement learning that employs backwards stagewise estimation to identify sequences of actions that maximize some long-term reward. The method can be applied to sequential multipleassignment randomized trials to develop personalized adaptive treatment strategies (ATSs)-longitudinal practice guidelines highly tailored to time-varying attributes of individual patients. Sometimes, the basis for choosing which ATSs to include in a sequential multiple-assignment randomized trial (or randomized controlled trial) may be inadequate. Nonrandomized data sources may inform the initial design of ATSs, which could later be prospectively validated. In this paper, we illustrate challenges involved in using nonrandomized data for this purpose with a case study from the Center for International Blood and Marrow Transplant Research registry (1995)(1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007) aimed at 1) determining whether the sequence of therapeutic classes used in graft-versus-host disease prophylaxis and in refractory graft-versus-host disease is associated with improved survival and 2) identifying donor and patient factors with which to guide individualized immunosuppressant selections over time. We discuss how to communicate the potential benefit derived from following an ATS at the population and subgroup levels and how to evaluate its robustness to modeling assumptions. This worked example may serve as a model for developing ATSs from registries and cohorts in oncology and other fields requiring sequential treatment decisions.
A central problem in medical practice is that clinical trials testing one agent compared with some alternative might not elucidate the "best" treatment for a particular patient, because 1) treatment effects may vary within subgroups which may not have been considered in the trial; 2) the effect of patients' time-varying characteristics might dwarf the initial effect of the baseline subgroup to which they belonged; and 3) there may be delayed synergism or antagonism between the treatment examined in the trial and heterogeneous treatments not included in the data capture or analysis (1) . Therefore, it is challenging to apply traditional clinical trial methodology to address the question of "How can we optimize the sequence of specific treatments for specific patients?".
An adaptive treatment strategy (ATS), also called a "dynamic treatment regime," is a set of decision rules for allocating treatment where input includes fixed and time-varying patient characteristics and treatment history and output is a highly individualized recommendation made each time a treatment decision is needed. Elsewhere, we and others have described sequential multiple assignment randomized trial (SMART) methodology, which is uniquely suited to developing ATSs, with an emphasis on potential applications in the oncology field (1, 2) .
In many situations, information needed to study ATSs in a randomized trial may not be readily available. Sample size calculation for SMARTs is a matter of active research (1) . In the study of rare diseases, SMARTs may be infeasible because of the required sample size or the difficulty involved in coordinating a study across many institutions. Thus, exploratory analysis of nonrandomized data sources, such as registries and cohort studies, and reanalysis of multistage randomized controlled trials (RCTs) might be useful for devising ATSs and for planning practical SMARTs.
Our objective in this paper is to illustrate how one might use nonrandomized data from registries or cohorts to propose ATSs and how to evaluate the robustness of an estimated "optimal" ATS. To accomplish this, we took the example of sequential prevention and treatment of acute graft-versushost disease (GVHD), a frequent complication of allogeneic hematopoietic cell transplantation (AHCT), and tested the feasibility of implementing Q-learning algorithms with Center for International Blood and Marrow Transplant Research (CIBMTR) registry data, with the goal of proposing an ATS for immunosuppressive management that would maximize disease-free survival 2 years post-AHCT (3).
MOTIVATING EXAMPLE: GVHD PREVENTION AND TREATMENT
In AHCT, immunosuppressive therapeutics are often administered sequentially to prevent and (if needed) treat GVHD. Their delayed effects, potential synergy or antagonism, and appropriateness given the complex, evolving characteristics of individual patients remain poorly characterized. Moreover, because of limited monetary resources, logistical challenges, and the heterogeneity (yet relative scarcity) of patients who develop the most severe posttransplant complications, such as steroid-refractory GVHD, there is a dearth of large RCTs for guiding practice; registry data have likewise proven difficult to exploit for developing "precision medicine" approaches. Therefore, the long-standing problem of how best to prevent and treat acute GVHD is an important question to address by applying novel approaches to the study of registry data.
CIBMTR registry studies influence AHCT practice worldwide. The CIBMTR's history, its current structure, and the information collected on its Comprehensive Report Forms are described elsewhere (4) .
METHODS: Q-LEARNING
Q-learning is a reinforcement learning technique used to find the optimal sequence of actions from time-varying sets of possible actions. Although other frequentist (5-7), Bayesian (8, 9) , and semiparametric (10, 11) approaches to estimating optimal ATSs have been developed, Q-learning is appealing because of simplicity: It proceeds via a sequence of predictions (often performed using regression) and hence relies on familiar analytical approaches, accounting for time-dependent confounding at each treatment stage by recursively modeling the outcome on the covariates measured prior to the treatment allocation at that stage. That is, for each patient at each decision point, starting with the final decision and then working backwards in time, it assigns values to the expected outcome resulting from each possible pairing of 1) treatment choice with 2) the observations made on that patient up to the given decision point. See Table 1 for the required assumptions. Q-learning using observational data and discrete outcomes is described in detail elsewhere (3, 12) .
Briefly, considering 2 sequential decisions and a binary endpoint, longitudinal data on a single patient are given by the tra-
, where C j and O j ( j = 1, 2) denote the set of covariates measured prior to treatment beginning at the jth interval and Y ϵ {0, 1} is the outcome observed at the end of interval 2. A j is the set of actions (treatments), one of which could be assigned at the jth interval subsequent to observing O j . Possible actions within the set are represented by a kj . The current work uses a 2-level choice (i.e., A j ϵ {0, 1}). Covariates represented by O j interact with treatment (i.e., are treatment effect modifiers) and are called tailoring or prescriptive variables; they directly determine the optimal choice of a kj from A j . Those represented by C j do not interact with treatment but either confound the relationship between treatment and outcome or are risk factors for the outcome (note that risk factors are required for correct outcome model specification). Any variable included in O j may also be a confounding variable-that is, a shared independent cause of both treatment and outcome. The history at each interval is defined as
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where H 2,β = (C 1 , O 1 , A 1 , C 2 ) and H 2,ψ = O 2 are subsets of the stage 2 history vector, H 2 . It is standard in the ATS literature to assume that greater values of the outcome are more desirable, so we have coded our outcome as 1 for diseasefree survival and 0 for death or relapse. Had we chosen a more conventional coding, the optimal treatment would have been that which minimized the Q-function.
Having estimated the best stage-2 treatment, the "pseudooutcome"Ỹ i 1 of interval 1 is generated for each Q 2 patient i by maximizing the logit of the probability of success in the second interval under the patient's own optimal A 2 treatment, which might be the treatment actually administered or the counterfactual option, and setting is the set of all other variables needed to predict the outcome.Ỹ i 1 is not the binary predicted outcome under optimal treatment but rather the probability of the outcome given optimal treatment. The pseudo-outcome thus provides a way of ensuring that the first-stage treatment analysis compares patients fairly: Rather than take the observed outcome under the observed secondstage treatments (which varies across patients), we use the predicted probability of the positive outcome under the (estimated) best treatment. Thus, the stage 1 regression seeks to determine the relationship between stage 1 treatment and the final outcome measured sometime after the administration of stage 2 treatment, if we could force all patients to follow the same stage-2 treatment rule. In a continuous outcome setting, the pseudo-outcome has a direct interpretation in terms of an individual-level counterfactual outcome; in the discrete outcome setting, the pseudo-outcome can be viewed as an expected counterfactual (10, 13) .
The interval 1 parameters (β ψ ) , 1 1 are now estimated, using a generalized linear model to regress the pseudo-outcomeỸ i 1 on all baseline/confounding variables, all interval 1 treatments, and all interactions between interval 1 treatments and potential tailoring variables. Finally, the optimal first-stage decision rule is found by calculating, patient by patient, which A 1 treatment would yield the best outcome, using the regression parameter estimates (β ψ ) , Patients who are more likely to die are more often assigned the more intense treatment option, where propensity to die cannot be accurately measured and so cannot be accurately controlled for.
Missing confounder information

Censoring is noninformative
Conditional on patient history and measured covariates, the potential outcomes of those subjects who are censored follow the same distribution as those of subjects who are fully followed.
Patients who are lost to follow-up or ineligible for further treatment decisions are fundamentally different from those who remain in the study cohort over time.
Feasibility/positivity Sufficient numbers of both treated and untreated subjects must exist at every level of the treatment and covariate history, at each decision stage.
Theoretical: The study design prohibits certain subjects from receiving a particular treatment.
Practical: Few patients with a given covariate pattern are included in the study sample or are assigned a particular treatment.
Time ordering Treatment precedes outcome. The severity of the subject's condition is not remeasured immediately prior to initiation of the next treatment, so an improvement that happened prior to that next treatment is later falsely attributed to that treatment.
Correct specification of all models
Unbiased and efficient estimated parameters Failure to choose the correct functional form
Failure to include an important tailoring variable b a Elaboration on these assumptions is presented elsewhere (34, 35) . b Realize, however, that "perfection is the enemy of the good." While including all necessary tailoring variables is vital to estimating the true optimal treatment strategy, there might also be value in restricting the included variables to those that are convenient and cost-effective to measure in routine clinical practice.
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Tailoring variables
Typically, subject matter knowledge is used to select a parsimonious set of tailoring variables, O j , that are likely to modify the relationship between treatment and the outcome and are available in routine clinical practice. If many variables are included in O j , the model could become unstable; variable selection approaches (e.g., see Gunter et al. (14)) could be used to eliminate unnecessary variables, although this technique has not been adopted due to computational complexity.
Expected results
For each patient, Q-learning generates an estimate ofâ j opt so that, for example, if the patient did not receive optimal stage 1 treatment, the stage 2 decision rule could still be applied. The algorithm also estimates the probability of response (e.g., survival) under the optimal ATS on a patientspecific level. Importantly, the pseudo-outcomes under the different treatment options can be compared and aggregated across patients to obtain population-level estimates.
CASE STUDY ANALYSIS Patient selection and treatment definition
The CIBMTR selected 11,141 patients who had undergone AHCT between 1995 and 2007 and had been retrieved for a study on chronic GVHD. Our study was approved by the CIBMTR Committee on Graft-versus-Host Disease and the McGill University Research Ethics Board. Eligible diagnoses included acute myeloid leukemia and myelodysplastic syndrome; 9,563 patients were retained for analysis. Web Appendix 1 (sections 1 and 2), available at https://academic. oup.com/aje, provides details of patient selection and the analysis.
Our analysis focused on 2 stages of treatment: 1) GVHD prophylaxis and 2) second-line, or salvage, treatment for persons who developed GVHD and experienced unsuccessful first-line treatment. The goal was to maximize each patient's probability of 2-year disease-free survival (2y-DFS), meaning freedom from death or cancer relapse, measured from the day of graft infusion. We did not attempt to learn about tailoring first-line therapy because there was little variability in first-line GVHD treatment (92% received corticosteroids and 85% received a calcineurin inhibitor). Over 30 different agents administered for GVHD prophylaxis or salvage treatment were assigned to one of 2 groups: "nonspecific, highly T-cell lymphodepleting" (NHTL) therapeutics or "standard" therapeutics. Thus, the treatment options considered are (A 1 ; if GVHD that requires salvage, then A 2 ), where A 1 is either NHTL prophylaxis or standard prophylaxis and A 2 is either NHTL salvage or standard salvage therapy.
Model development and fitting
The first interval (Q 1 ) was defined as the time from graft infusion to diagnosis of steroid-refractory acute GVHD or last follow-up, whichever occurred first. The second interval (Q 2 ) was defined as the time from diagnosis of steroidrefractory acute GVHD to last follow-up.
In developing the logistic regression models, interactions between treatment with graft source, conditioning intensity, disease status, human leukocyte antigen match, and donor relationship were a priori deemed important to include in the model. Some initial model exploration was performed to determine whether, for example, polynomial transformations or some potential confounders would be retained in the set C j (see Web Appendix 1, section 6.3).
Missing data were addressed using inverse-probability-ofcensoring weights for those individuals who were lost to followup and multiple imputation by chained equations for all other missingness. Figure 1 shows the treatment-and-response trajectories experienced by patients in the cohort. The Q 2 model included 36 patients who were lost to follow-up after receiving acute GVHD salvage treatment but before the 2-year mark. Inverseprobability-of-censoring weights were calculated to account for their absence from the Q 2 model. To fit the weighted Q 2 model using data from fully observed salvage patients who relapsed or died before 2 years or were alive beyond 2 years, the observed 2y-DFS status with NHTL (if they received NHTL) salvage or with standard (if they received standard) salvage was used as the outcome.
Next, using that weighted model, we predicted pseudooutcomes for all patients who required salvage treatment. The pseudo-outcomes fall within the interval [0, 1] and can be interpreted as the probability that a given patient will survive for 2 years disease-free given his/her baseline covariates and observed prophylaxis, assuming optimal salvage treatment. Each patient's Q 1 outcome was taken as follows: 1) For fully observed patients who did not require salvage treatment, the observed outcome (alive = 1 or deceased/relapsed = 0) was used. 2) For fully observed patients who required salvage treatment and were followed through 2 years and those who required salvage treatment but were lost to follow-up before 2 years, the larger of the 2 pseudo-outcomes from Q 2 (those being the outcome under NHTL salvage and the outcome under standard salvage)-that is, the predicted outcome under optimal interval treatment,
opt -was used. The Q 1 model was fitted by means of regression with inverseprobability-of-censoring weights and used to predict the probability of 2y-DFS for each patient in the cohort under NHTL and under standard prophylaxis to determine which prophylaxis treatment led to the higher survival probability for each patient. All work was performed using R, versions 3.0.1-3.1.2 (R Foundation for Statistical Computing, Vienna, Austria) (15) . Confidence intervals were based on percentiles computed using a nonparametric bootstrap with 500 resamples. Web Appendix 2, section 3.1, shows assessment of model fit.
RESULTS
Censoring
Type of GVHD prophylaxis or salvage did not significantly predict censoring. Several factors were associated with the probability of being censored prior to the second interval; fewer . Part B shows the observed trajectories for the patients who received standard GVHD prophylaxis. In each panel, the A 1 band contains patients eligible for the Q 1 model, while the A 2 band contains patients eligible for the Q 2 model (i.e., only steroid-refractory acute GVHD patients). Between A 1 and A 2 , boxes with dashed borders represent patients who were censored during the Q 1 interval for model-fitting purposes because they did not die and did not go on to A 2 (due to either being lost to follow-up (LTFU) or never developing steroid-refractory GVHD) or because they were treated for chronic GVHD (cGVHD) before acute GVHD (aGVHD), making them ineligible for A 2 . After A 2 , dashed borders represent patients who were censored during the Q 2 interval for model-fitting purposes because they were LTFU after receiving salvage treatment. Pseudo-outcomes were predicted for all salvage patients (A 2 band) using the Q 2 model and for all cohort patients (A 1 band) using the Q 1 model, using inverse-probability-of-censoring weights to accommodate LTFU and Q 2 -ineligible patients. Abbreviations: CI, confidence interval; GVHD, graft-versus-host disease; HLA, human leukocyte antigen; NA, not applicable; NHTL, nonspecific, highly T-cell lymphodepleting; NT, not tested; RIC, reduced-intensity conditioning; RR, relative risk.
a The left-hand section of the table refers to the "main effects" terms, while the right-hand section refers to the combined main effect of NHTL and the interaction with each patient characteristic (covariate level).
b This section shows the combined parameter estimates for tailoring variables with NHTL prophylaxis-that is, the result of the main effects and of interactions between the characteristic and the class of prophylaxis treatment, calculated as RR = β β ψ ψ β β a expit(ˆ+ˆ+ (ˆ+ˆ) )/expit(ˆ+ˆ)
, where βˆ0 is the model intercept, β n is the coefficient for the main effect of the candidate tailoring variable, ψ 0 is the coefficient for the main effect of NHTL prophylaxis, ψ n is the coefficient for the interaction of NHTL prophylaxis with the candidate tailoring variable, and action a = 1for NHTL prophylaxis while a = 0 for standard prophylaxis; n indexes tailoring variables. Tables 2 and 3 show the results of Q-learning applied to the decision of whether to use NHTL therapy for prophylaxis and/ or for salvage in multivariable analysis. The relative risks of 2y-DFS suggest that NHTL prophylaxis is detrimental at the population level (Table 2 ; relative risk = 0.88, 95% confidence interval (CI): 0.76, 0.98) but cannot confirm that NHTL salvage treatment is also detrimental (Table 3 ; relative risk = 0.80, 95% CI: 0.36, 1.10). Most candidate tailoring variables are not significantly different from 0. Notable exceptions are that NHTL prophylaxis appears detrimental in the setting of Cytomegalovirus (CMV) positivity and umbilical cord graft sources, as well as in reduced-intensity/nonmyeloablative transplant, perhaps because it increases serious infections in the former (16) (17) (18) and increases the incidence of cancer relapse in the latter (19) (20) (21) . However, considering only the point estimates, certain combinations of values of potential tailoring variables "tip the balance" in favor of using NHTL prophylaxis or NHTL salvage. In this way, the algorithm could identify patients who might benefit more from one intervention than another (Figure 2) . The Q 1 model predicted that 4,766 patients (50%) would have a higher probability of 2y-DFS with NHTL prophylaxis and 4,797 (50%) would fare better with standard prophylaxis (Figure 2A ). These proportions were stable (49%-50%) across models employing somewhat different predictors and different parameterizations of the predictors. The magnitude of the benefit was modest. Among patients predicted to benefit more from standard prophylaxis, the median absolute difference in 2y-DFS probability predicted under standard prophylaxis versus NHTL prophylaxis was 5% (range, nearly 0% to 16%). Likewise, among patients predicted to benefit more from NHTL prophylaxis, the median absolute difference in 2y-DFS probability predicted under NHTL prophylaxis versus standard prophylaxis was 4% (range, nearly 0% to 16%). A total of 4,322 (45%) patients were predicted to have 2y-DFS differences greater than or equal to 5%, and 1,120 (12%) were predicted to have 2y-DFS differences greater than or equal to 10%, with alternative prophylaxis options.
For the 1,411 patients requiring salvage treatment for acute GVHD, the Q 2 model predicted that 506 patients (36%) would have a higher probability of 2y-DFS with NHTL prophylaxis and 905 (64%) would fare better with standard prophylaxis ( Figure 2B ). These proportions were fairly stable (33%-37% favoring NHTL) across models employing different predictors and different parameterizations of the predictors. Although intuitively the interaction section of Table 3 (last 2 columns) suggests that NHTL is uniformly detrimental (recall that the relative risks represent the relative risk of survival), when the patient-specific linear combinations of main and interaction terms are calculated, NHTL can trump standard salvage treatment. The contrast between predicted 2y-DFS for the alternative salvage choices was often substantial (but variability was great due to smaller sample size). Among patients predicted to benefit more from standard salvage, the Abbreviations: CI, confidence interval; GVHD, graft-versus-host disease; HLA, human leukocyte antigen; NA, not applicable; NHTL, nonspecific, highly T-cell lymphodepleting; NT, not tested; RIC, reduced-intensity conditioning; RR, relative risk.
b Patients who developed chronic GVHD requiring systemic treatment before developing acute GVHD were censored from this analysis, as described in Figure 1 .
c This section shows the combined parameter estimates for tailoring variables with NHTL salvage-that is, the result of the main effects and of interactions between the characteristic and the class of salvage treatment, calculated as
, where β 0 is the model intercept, β n is the coefficient for the main effect of the candidate tailoring variable, ψ 0 is the coefficient for the main effect of NHTL salvage, ψ n is the coefficient for the interaction of NHTL salvage with the candidate tailoring variable, and action a = 1 for NHTL salvage while a = 0 for standard salvage; n indexes tailoring variables.
Am J Epidemiol. 2017;186(2):160-172 Q-Learning With Cohort and Registry Data 167 absolute difference in 2y-DFS probability predicted under standard salvage versus NHTL salvage was a median of 9% (range, nearly 0% to 57%). Similarly, among patients predicted to benefit more from NHTL salvage, the absolute difference in 2y-DFS probability predicted under NHTL salvage versus standard salvage was a median of 7% (range, nearly 0% to 41%). For 898 (63%) patients, the predicted 2y-DFS with alternative salvage options differed by at least 5%, and for 606 (42%) patients, it differed by at least 10%. These results suggest that the personalized ATS affords slightly superior 2y-DFS for the population (41.97%, 95% CI: 41.16, 44.22) compared with the best fixed strategy, employing standard prophylaxis with NHTL salvage (39.43%, 95% CI: 37.95, 40.35). These population-level estimates are computed in the same data set as that used to build the models; an independent validation cohort would be needed to confirm these findings.
Stability of personalized recommendations
The ATS was derived following averaging across multiple imputed data sets. The stability of the patient-specific treatment recommendations across the different imputations provides limited reassurance about the robustness of these recommendations to small changes in covariate values (Web Appendix 2, section 3.2). Only 4% of patients received a conflicting prophylaxis recommendation in at least 1 of the 5 imputations, and 6% received a conflicting salvage treatment recommendation in at least 1 of the 5 imputations.
Post-hoc consideration of sample size
Despite the very large registry available to us, post-hoc analyses suggested that the wide confidence intervals reported here may be attributed to lack of power, as the detection of interactions-which is what we seek in estimating an ATSrequires very large samples (Web Appendix 2, section 3.3).
DISCUSSION
To develop an ATS with observational data, we suggest a multistep process (Appendix Table 1 ). This work illustrates how this process can yield highly personalized treatment recommendations. For example, our model predicted that a 9-year-old, CMV-negative male recipient of an unrelated female, partially matched, CMV-negative peripheral blood graft for treatment of advanced acute myeloid leukemia after cyclophosphamide plus total-body irradiation myeloablative conditioning would have a 16% greater chance of 2y-DFS if given NHTL prophylaxis. A 20-year-old CMV-positive female recipient of a human leukocyte antigen-identical, CMV-negative sibling peripheral blood graft for treatment of early acute myeloid leukemia after reduced-intensity busulfan-fludarabine was predicted to have superior 2y-DFS with standard prophylaxis (45%) as compared with NHTL prophylaxis (33%).
Our goal was to introduce readers to the concept of ATSs and one of the methods used to estimate such treatment sequences, Q-learning. Q-learning is easily implemented and flexible, adaptable to continuous (22, 23) , discrete (12) , and time-to-event (24) outcomes, as well as continuous or multicategory exposures. Analysis is not restricted to regression: Q-learning can be implemented using any form of prediction (e.g., trees). Many alternatives to Q-learning are available. G-computation (whether Bayesian (25, 26) or frequentist (27) in terms of implementation) is conceptually straightforward, but it requires estimation of the joint distribution of all tailoring and confounding variables at each interval; for this reason, the approach has not found favor in practice, as misspecification of any of these potentially high-dimensional models can lead to incorrect conclusions (10) . Semiparametric approaches include g-estimation (10), dynamic marginal structural models (28) (29) (30) , and dynamic weighted ordinary least squares (31); these approaches offer advantages, as each can be implemented in a doubly robust manner. Of these, g-estimation is perhaps the most difficult to understand; however, an R package has been developed with which to implement g-estimation and dynamic weighted ordinary least squares with an arbitrary number of treatment intervals for either binary or continuous (dose) treatments (32) . In contrast, the dynamic marginal structural model approach and related approaches rely on familiar techniques, such as inverse weighting, but they require considering preprocessing of the data prior to analysis and are difficult to implement with a large or varying number of tailoring variables.
This article is not intended to propose a definitive ATS for acute GVHD prophylaxis and treatment. To do so would require a more recent cohort treated with contemporary practices and measurement of key confounders that are currently missing from CIBMTR Comprehensive Report Forms (cf. Web Appendix 2, section 3.4). That caveat aside, the estimated increased probability of survival from following the optimal ATS to prevent and treat GVHD is large enough (≥10%) for a substantial fraction of patients to justify further research in this area, even though, on a population level, following the optimal ATS compared with the "worst" policy of "NHTL prophylaxis/ standard salvage for everyone" is predicted to improve 2y-DFS by approximately 4% (41.97% 2y-DFS vs. 37.83% 2y-DFS). A 2-arm RCT randomizing 1:1 between the ATS and this "worst" policy with 80% power to detect such a difference (type I error rate 0.05, pooled standard deviation 0.016) would require approximately 4,500 patients. Web Appendix 2, section 3.3, offers further guidance on power/sample size, taking into account tailoring variables. Simulations can also provide a useful tool for understanding the needed statistical power and potential gains from ATSs. However, neither RCTs nor large SMARTs are easily executable in the AHCT field, as most transplant centers perform few allogeneic transplants (from <25 to about 100) annually. Happily, answering relevant questions is feasible in the registry setting; the CIBMTR . From left to right: Patient-specific prophylaxis and GVHD salvage treatment determined by the adaptive treatment strategy (ATS) estimated via the Q-learning algorithm; universal nonspecific highly T-cell lymphodepleting (NHTL) prophylaxis and salvage treatment; universal NHTL prophylaxis and standard salvage treatment; universal standard prophylaxis and standard salvage treatment; and universal standard prophylaxis and NHTL salvage treatment. The error bars represent 95% confidence intervals. The ATS achieves a slightly higher probability of 2-year disease-free survival than the alternative policies. Specifically, the risk differences (in favor of survival) are 3.9% (95% confidence interval (CI): 2.0, 6.1) for the ATS compared with a policy of universal NHTL prophylaxis and salvage treatment, 4.8% (95% CI: 2.8, 7.2) for the ATS compared with universal NHTL prophylaxis and standard salvage treatment, 4.1% (95% CI: 2.5, 5.9) for the ATS compared with universal standard prophylaxis and standard salvage treatment, and 3.5% (95% CI: 2.0, 5.1) for the ATS compared with universal standard prophylaxis with NHTL salvage treatment.
Am J Epidemiol. 2017;186(2):160-172 Q-Learning With Cohort and Registry Data 169 currently includes more than 425,000 patients, banks more than 42,000 paired patient-donor blood samples, and curates thousands of patients annually. An ATS estimated from registry data could be validated to some extent through additional observational studies. For example, results from institutions that implemented the proposed ATS could be compared with those from institutions that did not, provided there exist sufficient numbers of institutions whose practices are compatible with the proposed ATS. Alternatively, institutions might implement the ATS for a year (or more), withdraw it for a year (or more), and then reimplement it for a year (or more). If outcomes are better for the patients who were treated in the years when the algorithm was in place, and that benefit disappeared in the years when the algorithm was withdrawn, that would serve as circumstantial evidence of the ATS's value. One logistical difficulty with such an approach is that a patient should always be treated according to his or her initial treatment strategy, such that if treatment began in an "ATS year" and continued into a "withdrawn year," the ATS should continue to be followed for that patient. That is, the ATS needs to be available to "study" patients at all times.
The originality of this work lies in having used registry data in combination with a highly innovative analytical approach. In reality, clinicians engage in sequential treatment decisionmaking over time based on accruing observations about the individual patient; providing data-driven evidence to support this form of decision-making is critical. Like the CIBMTR data, clinical practice encompasses far more diverse patient characteristics than are found in the typically homogeneous patient populations on which RCTs generally focus. Finally, in clinical practice, there are usually many possible treatments at each decision point, but RCTs usually limit these possibilities sharply and thus fail to capture the complexity of real-life clinical decisions. Q-learning and similar approaches can be harnessed to make decisions in the face of uncertainty more rationally by making the relationship between a combination of patient-specific characteristics and the outcome explicit and formalizing the decision-making process in an evidencebased manner.
